"Effect of Palbociclib (PAL) + Endocrine Therapy (ET) on Time to Chemotherapy (TTC) across Subgroups of Patients (pts) with Hormone Receptor-positive/human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) Advanced Breast Cancer (ABC): Post Hoc Analyses from PALOMA-2 (P2) and PALOMA-3 (P3)" by Reshma Mahtani

Article

Effect of Palbociclib (PAL) + Endocrine Therapy (ET) on Time to Chemotherapy (TTC) across Subgroups of Patients (pts) with Hormone Receptor-positive/human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) Advanced Breast Cancer (ABC): Post Hoc Analyses from PALOMA-2 (P2) and PALOMA-3 (P3)

Annals of Oncology / European Society for Medical Oncology (ESMO) Virtual Conference (2021)

Reshma Mahtani, Baptist Health South Florida

Link

Abstract

H. Rugo; S. Im; A. Joy; S. Yaroslav; J. Walshe; B. Sleckman; S. Loi; P. Theall; S. Kim; X. Huang; E. Bananis; R. Finn; V. Dieras

Disciplines

Medicine and Health Sciences

Publication Date

September 1, 2021

Citation Information

Reshma Mahtani. "Effect of Palbociclib (PAL) + Endocrine Therapy (ET) on Time to Chemotherapy (TTC) across Subgroups of Patients (pts) with Hormone Receptor-positive/human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) Advanced Breast Cancer (ABC): Post Hoc Analyses from PALOMA-2 (P2) and PALOMA-3 (P3)" Annals of Oncology / European Society for Medical Oncology (ESMO) Virtual Conference Vol. 32 Iss. suppl. 5 (2021)
Available at: http://works.bepress.com/reshma-mahtani/55/